Why do Servier bets one Billion euros on Revolutionary Diabetes Drugs Delivery Device?

15/11/2014 - 2 minutes

The French company Servier wants to invest one billion euros by a partnering with the American company Intarcia regarding their subcutaneous implant for diabetes. This is a breakthrough micropump, the first device without injection able to deliver the molecule Exenatide during one year.

It is a huge step forward in treating type 2 diabetes. Indeed, most people forget to take their pills or to measure their blood glucose level. Moreover, diabetes affects more than 382 million people worldwide and will reach 600 million people in 2035. The global market is increasing and exceeds 40 billion euros in 2013.

Under the agreement, Boston-based Intarcia will receive $171 million upfront and $230 million for three early-stage regulatory milestones. Additional development, regulatory and sales milestones could lead the entire deal to $1 billion.

Both companies will share running cost of studies that compare ITCA 650 to other leading diabetes treatments. Intarcia will continue to lead the current phase 3 trials of ICTA 650 and the effort to seek regulatory approval in the U.S.,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!